|
시장보고서
상품코드
2078901
종양 미세환경 시장 : 암 유형별, 표적별, 치료법별, 최종사용자별, 지역별Tumor Microenvironment Market, By Cancer Type, By Target, By Therapy, By End User, By Geography |
||||||
종양 미세환경 시장은 2026년에 21억 1,000만 달러, 2033년까지 50억 1,000만 달러에 이를 것으로 예상됩니다. 또한, 2026-2033년 CAGR 13.1%를 기록할 전망입니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준연도 : | 2025년 | 2026년 시장 규모 : | 21억 1,000만 달러 |
| 과거 데이터 기간 : | 2020-2024년 | 예측 기간 : | 2026-2033년 |
| 예측 기간(2026-2033년) CAGR : | 13.10% | 2033년 시장 규모 예측 : | 50억 1,000만 달러 |
종양 미세환경은 서로 상호작용하며, 종양의 발생과 진행에 있어 매우 중요한 역할을 하는 다양한 세포성 및 비세포성 구성 요소로 이루어진 복잡한 생태계입니다. 이러한 구성 요소에는 면역 세포, 섬유아세포, 혈관, 세포외 기질, 신호 전달 분자 등이 포함됩니다. 암을 효과적으로 치료할 수 있는 표적 치료법을 개발하기 위해서는 종양 미세환경을 이해하는 것이 필수적입니다. 최근, 종양 세포와 그 주변 환경 간의 이러한 역동적인 상호작용의 중요성이 인식됨에 따라, 종양 미세환경에 대한 연구가 큰 주목을 받고 있습니다. 현재는 종양 미세환경이 혈관신생, 면역 반응, 전이, 약물 내성 등 다양한 과정에 영향을 미칠 수 있다는 사실이 밝혀졌습니다.
시장 역학:
종양 미세환경 시장은 여러 요인의 뒷받침을 받아 향후 몇 년 동안 상당한 성장이 예상됩니다. 주요 촉진요인 중 하나는 전 세계 암 발병률 증가입니다. 세계보건기구(WHO)의 2020년 보고서에 따르면, 암은 전 세계적으로 주요 사망 원인 중 하나이며, 매년 약 1,000만 명의 신규 환자와 600만 명의 사망자가 보고되고 있습니다. 이로 인해 암을 이해하고 치료하기 위한 첨단 기법에 대한 수요가 크게 증가하면서 시장 성장을 주도하고 있습니다.
그러나 높은 연구개발비용, 엄격한 규제 요건, 종양 미세환경 연구에서 동물 모델 사용과 관련된 윤리적 우려 등의 요인으로 인해 시장 성장이 저해될 가능성이 있습니다. 또한, 숙련된 전문가의 부족이나 조사 방법의 표준화가 미흡한 점도 시장 성장에 있어 과제가 될 수 있습니다.
이러한 과제가 있음에도 불구하고, 종양 미세환경 시장에는 큰 성장 기회가 있습니다. 다광자 현미경이나 생체 이미징 등의 영상 기술 발전 덕분에, 연구자들은 종양 미세환경을 실시간으로 고해상도로 연구할 수 있게 되었습니다. 또한, 맞춤형 의료의 부상과 정밀 종양학에 대한 관심이 높아짐에 따라, 종양 미세환경에 대한 정보를 제공할 수 있는 바이오마커에 대한 수요가 생겨나면서 시장 성장을 더욱 촉진하고 있습니다.
또한, 시장에 진출한 각 기업은 제휴 등 비유기적 전략을 전개하고 있으며, 이는 예측 기간 동안 전 세계 종양 미세환경 시장의 성장을 가속화할 것으로 전망됩니다. 예를 들어, 2023년 3월 20일, 독일의 생명공학 기업인 BioNTech SE와 임상 단계의 바이오의약품 기업인 OncoC4, Inc.는 OncoC4사의 차세대 항-CTLA-4 단일클론 항체 후보물질인 'ONC-392'를 각종 암 적응증에 대한 단독 요법 또는 병용 요법으로 개발·상용화하기 위한 전 세계 독점 라이선스 및 제휴 계약을 체결했다고 발표했습니다. CTLA-4는 다양한 기전을 통해 면역 세포의 활성을 억제하는 분자입니다. OncoC4사의 CTLA-4 항체 후보 ‘ONC-392'는 종양 미세환경 내의 면역억제성 T세포(조절 T세포, 'Treg')를 제거하는 동시에, 정상 조직 내의 Treg는 보존하는 것을 목적으로 합니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 성장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하고 있는 경쟁 전략에 관한 중요한 인사이트도 제공합니다.
- 본 조사에서는 다음의 매개변수(기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략)를 바탕으로 전 세계 종양 미세환경 시장의 주요 기업 프로파일을 소개했습니다.
- 이 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- "세계 종양 미세환경 시장” 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진출기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자들은 전 세계 종양 미세환경 시장 분석에 활용되는 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 전제조건
제2장 시장 전망
제3장 시장 역학, 규제 및 동향 분석
제4장 종양 미세환경 시장 : 암 유형별, 2021년-2033년
제5장 종양 미세환경 시장 : 타겟별, 2021년-2033년
제6장 종양 미세환경 시장 : 치료법별, 2021년-2033년
제7장 종양 미세환경 시장 : 최종사용자별, 2021년-2033년
제8장 종양 미세환경 시장 : 지역별, 2021년-2033년
제9장 경쟁 구도
제10장 섹션
LSH 26.07.10Tumor Microenvironment Market is estimated to be valued at USD 2.11 Bn in 2026 and is expected to reach USD 5.01 Bn by 2033, growing at a compound annual growth rate (CAGR) of 13.1% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 2.11 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 13.10% | 2033 Value Projection: | USD 5.01 Bn |
The tumor microenvironment is a complex ecosystem consisting of various cellular and non-cellular components that interact with each other and play a crucial role in tumor development and progression. These components include immune cells, fibroblasts, blood vessels, the extracellular matrix, and signaling molecules. Understanding the tumor microenvironment is essential for developing targeted therapies that can effectively treat cancer. The study of the tumor microenvironment has gained significant attention in recent years, as researchers have realized the importance of this dynamic interaction between tumor cells and their surroundings. It is now evident that the tumor microenvironment can influence various processes, such as angiogenesis, immune response, metastasis, and drug resistance.
Market Dynamics:
The tumor microenvironment market is expected to witness significant growth in the coming years, driven by several factors. One of the major drivers is the increasing incidence of cancer worldwide. According to the World Health Organization (WHO), 2020, cancer is one of the leading causes of death globally, with approximately 10 million new cases and 6 million deaths reported annually. This has led to a substantial demand for advanced methods to understand and treat cancer, thereby driving market growth.
However, market growth can be restrained by factors, such as the high cost of research and development, stringent regulatory requirements, and ethical concerns related to the use of animal models in tumor microenvironment studies. Additionally, the limited availability of skilled professionals and the lack of standardization in research methodologies can pose challenges to market growth.
Despite these challenges, the tumor microenvironment market offers significant opportunities for growth. Technological advancements in imaging techniques, such as multiphoton microscopy and intravital imaging, have enabled researchers to study the tumor microenvironment in real-time and high resolution. Moreover, the emergence of personalized medicine and the increasing focus on precision oncology have created a demand for biomarkers that can provide insights into the tumor microenvironment, further driving market growth.
Moreover, market players are engaged in conducting inorganic strategies such as collaborations, and this is expected to increase the growth of the global tumor microenvironment market over the forecast period. For instance, on March 20, 2023, BioNTech SE, a German biotechnology company and OncoC4, Inc., a clinical-stage biopharmaceutical company, announced that they had entered into an exclusive worldwide license and collaboration agreement to develop and commercialize OncoC4's next-generation anti-CTLA-4 monoclonal antibody candidate, ONC-392, as monotherapy or combination therapy in various cancer indications. CTLA-4 is a molecule that inhibits the activity of immune cells via various mechanisms. OncoC4's CTLA-4 antibody candidate, ONC-392, aims to delete immunosuppressive T cells (regulatory T cells, "Tregs") in the tumor microenvironment but spare Tregs in healthy tissues.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global tumor microenvironment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Thermo Fisher Scientific, Illumina, Danaher Corporation, Merck KGaA , BD Biosciences, Promega Corporation, Bio-Techne Corporation , Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd, QIAGEN N.V., Sartorius AG, PerkinElmer, Miltenyi Biotec, Cell Signaling Technology, BioLegend, Abcam, Takara Bio, Fluidigm Corporation, NanoString Technologies, 10x Genomics, and Bethyl Laboratories
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global tumor microenvironment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global tumor microenvironment market
Detailed Segmentation:
- By Cancer Type (Revenue, USD Bn, 2021 - 2033)
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Bladder Cancer
- Others (Melanoma, Kidney cancer, Ovarian cancer etc.)
- By Target (Revenue, USD Bn, 2021 - 2033)
- T Cells
- Tumor-Associated Macrophages
- Myeloid-Derived Suppressor Cells
- Cancer-Associated Fibroblasts
- Regulatory T Cells
- Others (Tumor-associated neutrophils, Dendritic cells etc.)
- By Therapy (Revenue, USD Bn, 2021 - 2033)
- Monoclonal Antibodies
- Cytokines
- Cancer Vaccines
- Oncolytic Viruses
- Adoptive Cell Therapies
- Others (Gene therapies, Immunomodulators,Checkpoint inhibitors etc.)
- By End User (Revenue, USD Bn, 2021 - 2033)
- Biopharmaceutical Companies
- Hospitals
- Diagnostic Laboratories
- Research Institutes
- Contract Research Organizations (CROs)
- Others (Academic Institutes and Others)
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players
- Thermo Fisher Scientific
- Illumina
- Danaher Corporation
- Merck KGaA
- BD Biosciences
- Promega Corporation
- Bio-Techne Corporation
- Bio-Rad Laboratories
- F.Hoffmann-La Roche Ltd
- QIAGEN N.V.
- Sartorius AG
- PerkinElmer
- Miltenyi Biotec
- Cell Signaling Technology
- BioLegend
- Abcam
- Takara Bio
- Fluidigm Corporation
- NanoString Technologies
- 10x Genomics
- Bethyl Laboratories
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Tumor Microenvironment, By Cancer Type
- Market Tumor Microenvironment, By Target
- Market Tumor Microenvironment, By Therapy
- Market Tumor Microenvironment, By End User
- Market Tumor Microenvironment, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing cancer prevalence
- High costs associated with reagents
- Adoption of AI and machine learning
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Tumor Microenvironment Market , By Cancer Type, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022-2033
- Segment Trends
- Lung Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Colorectal Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Breast Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Prostate Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Bladder Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others (Melanoma, Kidney cancer, Ovarian cancer etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
5. Tumor Microenvironment Market , By Target, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- T Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Tumor-associated Macrophages
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Myeloid-Derived Suppressor Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Cancer-Associated Fibroblasts
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Regulatory T Cells
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others (Tumor-associated neutrophils, Dendritic cells etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
6. Tumor Microenvironment Market , By Therapy, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Monoclonal Antibodies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Cytokines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Cancer Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Oncolytic Viruses
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Adoptive Cell Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others (Gene therapies, Immunomodulators,Checkpoint inhibitors etc.)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
7. Tumor Microenvironment Market , By End User, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
- Biopharmaceutical Companies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Hospitals
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Diagnostic Laboratories
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Research Institutes
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Contract Research Organizations (CROs)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
- Others (Academic Institutes and Others)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033,(US$ Bn)
8. Tumor Microenvironment Market , By Region, 2021 - 2033, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Country 2022 -2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East & Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Cancer Type, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Therapy, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2021 - 2033,(US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Bn)
- GCC Countries
- Israel
- South Africa
- North Africa
- Central Africa
- Rest of Middle East
9. Competitive Landscape
- Thermo Fisher Scientific
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Illumina
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Danaher Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Merck KGaA
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- BD Biosciences
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Promega Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bio-Techne Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bio-Rad Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Hoffmann-La Roche Ltd
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- QIAGEN N.V.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sartorius AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- PerkinElmer
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Miltenyi Biotec
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cell Signaling Technology
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- BioLegend
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Abcam
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Takara Bio
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Fluidigm Corporation
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- NanoString Technologies
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- 10x Genomics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bethyl Laboratories
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
